In May 2021, amivantamab, a human bispecific antibody for EGFR and mesenchymal-epithelial transition (MET) receptor, was the first drug approved by US Food and Drug Administration (FDA) for patients with advanced or metastatic NSCLC with exon 20 insertion mutations following progression after platinum-based chemotherapy [15]. Here, EGFR is linked to non-small cell lung carcinoma.